Biomarker of Lung Injury in ARDS Patients Receiving ECMO Support
The goal of this project is to find a marker expression that the investigators can use to trace symptom progression and develop a more efficient therapy to enhance ARDS patient survival rate and better post-ICU life quality.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Biomarker of Lung Injury in ARDS Patients Receiving ECMO Support|
- Mortality or multi-organ failure [ Time Frame: 7 days ] [ Designated as safety issue: No ]Patients who survived for more than 7 days after ECMO treatment were defined as survival, and non-survival patients were defined as expired or multiple organ failure incompatible with life within 7 days after ECMO installation.
Biospecimen Retention: Samples With DNA
Plasma, Cell, BALF, Urine
|Study Start Date:||October 2011|
|Estimated Study Completion Date:||April 2015|
|Estimated Primary Completion Date:||April 2015 (Final data collection date for primary outcome measure)|
The investigators will first identify acute respiratory distress syndrome (ARDS) patients receiving ECMO support in ICU at National Taiwan University Hospital, and then collect blood, urine and bronchioalveolar lavage fluid (BALF) samples at different time points: before setting up ECMO, 2, 6, 12, 24, 72 hours,5 and 14 days after ECMO installment, time to wean ECMO and the day removing ECMO and leaving ICU. From the samples, the free radicals, cytokines (IL-1, IL-6, IL-8, IL-18,tumor necrosis factor-α, transforming growth factor-β), and inflammasome- related markers, immune cell responses and other biochemical markers would be measured. The novel biomarkers to predict the outcome of the patient will be identified.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01967602
|National Taiwan University Hospital||Recruiting|
|Contact: Shuenn-Wen Kuo, MD 0972651448 email@example.com|
|Principal Investigator:||Shuenn-Wen Kuo, MD||National Taiwan University Hospital|